Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir in hospitalized patients with moderate COVID-19
ISRCTN85762140Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of remdesivir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Odds ratio for improvement on a 7-point ordinal scale. Started Mar 2020; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN85762140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85762140.